Medytox fat-reduction injection Neubeauju sees rapid sales rise post-GLP-1

Medytox's fat-reduction injection Neubeauju surpassed 10,000 vials in cumulative sales by June 2026, driven largely by patients seeking localized contouring after GLP-1 weight loss. Launched in late March 2026 following its September 2025 approval by the South Korean Ministry of Food and Drug Safety, the cholic acid-based injectable achieved more than half of its annual revenue target in two months. Approximately 300 South Korean medical institutions have already adopted the product. Neubeauju is formulated at a physiological pH of 7.4 to minimize injection pain, and it excludes common allergy-triggering excipients like benzyl alcohol and benzethonium chloride. For practices navigating the post-GLP-1 landscape, this rapid adoption highlights a shifting patient demographic. Instead of relying solely on systemic weight loss, patients are actively seeking targeted injectables to resolve localized volume loss and skin sagging, particularly around the double chin. Tracking the adoption of cholic acid formulations offers a practical template for clinics looking to address these specific, post-weight-loss contouring complaints with less treatment discomfort.

Source: Seoul Economic Daily, https://www.sedaily.com